Treating Bipolar 1 Disorder

By: 3BL Media

Healthcare professionals share perspectives on providing care for people living with bipolar 1 disorder

SOURCE: Alkermes

DESCRIPTION:

Check out a new infographic with findings from our latest survey conducted in partnership with The Harris Poll and Depression and Bipolar Support Alliance – National Headquarters. Learn what healthcare providers (HCPs) had to say about treating individuals with bipolar 1 disorder: https://bit.ly/383gMvq

About Alkermes
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Tweet me: .@Alkermes has created a new infographic from findings with @HarrisPoll and @DBSAlliance on what healthcare providers (HCPs) had to say about treating individuals with #bipolar 1 disorder: https://bit.ly/3FPKj8a

KEYWORDS: NASDAQ: ALKS, Alkermes

Text: Treating Bipolar 1 Disorder, Healthcare Professionals Share Perspectives on Providing Care for People Living with Bipolar 1 Disorder

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  204.98
-5.13 (-2.44%)
AAPL  266.57
+1.99 (0.75%)
AMD  195.22
-4.93 (-2.46%)
BAC  51.23
-1.83 (-3.45%)
GOOG  311.50
-3.40 (-1.08%)
META  637.82
-17.84 (-2.72%)
MSFT  383.63
-13.60 (-3.42%)
NVDA  191.02
+1.20 (0.63%)
ORCL  140.85
-7.23 (-4.88%)
TSLA  395.83
-15.99 (-3.88%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.